Proteomic analysis in Alzheimer's disease and other dementias: a focus on sex-specific differences.

IF 7.6 1区 医学 Q1 CLINICAL NEUROLOGY
Aina Comas-Albertí, Albert Lladó, Diana Esteller-Gauxax, Sergi Borrego-Écija, Neus Falgàs, Farida Dakterzada, Agnès Pérez-Millan, Roger Puey, Tània Collet-Romà, Núria Guillén, Miquel Massons, Adrià Tort-Merino, Josep Maria Augé, Guadalupe Fernandez-Villullas, Bea Bosch, Raquel Ruiz-García, Laura Naranjo, Mircea Balasa, Gerard Piñol-Ripoll, Anna Antonell, Raquel Sánchez-Valle
{"title":"Proteomic analysis in Alzheimer's disease and other dementias: a focus on sex-specific differences.","authors":"Aina Comas-Albertí, Albert Lladó, Diana Esteller-Gauxax, Sergi Borrego-Écija, Neus Falgàs, Farida Dakterzada, Agnès Pérez-Millan, Roger Puey, Tània Collet-Romà, Núria Guillén, Miquel Massons, Adrià Tort-Merino, Josep Maria Augé, Guadalupe Fernandez-Villullas, Bea Bosch, Raquel Ruiz-García, Laura Naranjo, Mircea Balasa, Gerard Piñol-Ripoll, Anna Antonell, Raquel Sánchez-Valle","doi":"10.1186/s13195-026-02068-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Fluid protein studies in cerebrospinal fluid (CSF) and plasma have provided important insights into neurodegenerative dementias; however, there is a limited investigation of sex-related differences and cross-biofluid relationships. In Alzheimer's disease (AD), Lewy body dementia (LBD), and frontotemporal dementia (FTD), large-scale, sex-stratified analyses of paired CSF and plasma samples remain scarce. Using the multiplex and ultrasensitive capabilities of NULISAseq™ technology, this study aims to characterize sex- and disease-specific proteomic alterations associated with Central Nervous System (CNS) pathology to explore underlying mechanisms.</p><p><strong>Methods: </strong>CSF and plasma samples from 359 individuals with AD, LBD, FTD, and cognitively healthy controls were analyzed using the NULISAseq™ CNS Disease Panel 120. Differential protein expression analyses were conducted across diagnoses and stratified by sex, adjusting for relevant covariates. Spearman's correlation analyses were performed to assess concordance between CSF and plasma protein levels. All statistical analyses were conducted in R v4.4.3.</p><p><strong>Results: </strong>Differential protein expression analyses across diagnoses revealed two potential transdiagnostic biomarkers: ICAM1 in CSF and ANXA5 in plasma, showing consistent increases across AD, LBD, and FTD. Sex-stratified analyses in CSF showed modest changes, including higher CCL26, ANXA5, and IL10 in females with AD, and higher IL9, PRDX6, and CX3CL1 in males with AD. In LBD, females exhibited upregulation of ACHE, SFRP1, POSTN in both CSF and plasma. NPTX1 was identified as a potential CSF biomarker for FTD, showing downregulation particularly in males. In contrast, analyses stratified by sex in plasma displayed a larger number of proteins across all dementias, with females showing a higher number of upregulated inflammation-related proteins predominantly involved in cytokine signaling. Overall cross-fluid correlations were restricted to a small subset of proteins, indicating compartment-specific regulation.</p><p><strong>Conclusions: </strong>This study represents a large-scale, sex-stratified proteomic analysis of CSF and plasma across major neurodegenerative dementias using NULISAseq™ technology. The findings highlight sex-dependent biomarker patterns, particularly in plasma, and underscore the importance of incorporating sex as a biological variable in dementia research. Future studies should validate candidate proteins in independent cohorts, investigate their functional and mechanistic roles, and assess their utility for biomarker development and sex-tailored therapeutic strategies.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":" ","pages":""},"PeriodicalIF":7.6000,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's Research & Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13195-026-02068-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Fluid protein studies in cerebrospinal fluid (CSF) and plasma have provided important insights into neurodegenerative dementias; however, there is a limited investigation of sex-related differences and cross-biofluid relationships. In Alzheimer's disease (AD), Lewy body dementia (LBD), and frontotemporal dementia (FTD), large-scale, sex-stratified analyses of paired CSF and plasma samples remain scarce. Using the multiplex and ultrasensitive capabilities of NULISAseq™ technology, this study aims to characterize sex- and disease-specific proteomic alterations associated with Central Nervous System (CNS) pathology to explore underlying mechanisms.

Methods: CSF and plasma samples from 359 individuals with AD, LBD, FTD, and cognitively healthy controls were analyzed using the NULISAseq™ CNS Disease Panel 120. Differential protein expression analyses were conducted across diagnoses and stratified by sex, adjusting for relevant covariates. Spearman's correlation analyses were performed to assess concordance between CSF and plasma protein levels. All statistical analyses were conducted in R v4.4.3.

Results: Differential protein expression analyses across diagnoses revealed two potential transdiagnostic biomarkers: ICAM1 in CSF and ANXA5 in plasma, showing consistent increases across AD, LBD, and FTD. Sex-stratified analyses in CSF showed modest changes, including higher CCL26, ANXA5, and IL10 in females with AD, and higher IL9, PRDX6, and CX3CL1 in males with AD. In LBD, females exhibited upregulation of ACHE, SFRP1, POSTN in both CSF and plasma. NPTX1 was identified as a potential CSF biomarker for FTD, showing downregulation particularly in males. In contrast, analyses stratified by sex in plasma displayed a larger number of proteins across all dementias, with females showing a higher number of upregulated inflammation-related proteins predominantly involved in cytokine signaling. Overall cross-fluid correlations were restricted to a small subset of proteins, indicating compartment-specific regulation.

Conclusions: This study represents a large-scale, sex-stratified proteomic analysis of CSF and plasma across major neurodegenerative dementias using NULISAseq™ technology. The findings highlight sex-dependent biomarker patterns, particularly in plasma, and underscore the importance of incorporating sex as a biological variable in dementia research. Future studies should validate candidate proteins in independent cohorts, investigate their functional and mechanistic roles, and assess their utility for biomarker development and sex-tailored therapeutic strategies.

阿尔茨海默病和其他痴呆症的蛋白质组学分析:性别特异性差异的焦点。
背景:脑脊液(CSF)和血浆中的液体蛋白研究为神经退行性痴呆提供了重要的见解;然而,对性别相关差异和跨生物流体关系的研究有限。在阿尔茨海默病(AD)、路易体痴呆(LBD)和额颞叶痴呆(FTD)中,配对脑脊液和血浆样本的大规模、性别分层分析仍然很少。利用NULISAseq™技术的多重和超灵敏功能,本研究旨在表征与中枢神经系统(CNS)病理相关的性别和疾病特异性蛋白质组学改变,以探索潜在机制。方法:使用NULISAseq™CNS疾病面板120分析359例AD、LBD、FTD和认知健康对照患者的脑脊液和血浆样本。差异蛋白表达分析在诊断中进行,并按性别分层,调整相关协变量。采用Spearman相关分析评估脑脊液和血浆蛋白水平的一致性。所有统计分析均在R v4.4.3中进行。结果:不同诊断的差异蛋白表达分析揭示了两种潜在的跨诊断生物标志物:脑脊液中的ICAM1和血浆中的ANXA5,在AD、LBD和FTD中显示一致的增加。CSF的性别分层分析显示适度变化,包括女性AD患者的CCL26、ANXA5和IL10升高,男性AD患者的IL9、PRDX6和CX3CL1升高。在LBD中,女性脑脊液和血浆中ACHE、SFRP1、POSTN均出现上调。NPTX1被认为是FTD的潜在脑脊液生物标志物,在男性中表现出下调。相比之下,血浆中按性别分层的分析显示,所有痴呆症患者的蛋白质数量都更多,女性显示出更多的上调炎症相关蛋白质,主要参与细胞因子信号传导。总的跨流体相关性仅限于一小部分蛋白质,表明了室特异性调节。结论:该研究使用NULISAseq™技术对主要神经退行性痴呆患者的脑脊液和血浆进行了大规模、性别分层的蛋白质组学分析。这些发现强调了性别依赖的生物标志物模式,特别是在血浆中,并强调了将性别作为痴呆研究中的生物学变量的重要性。未来的研究应该在独立的队列中验证候选蛋白,调查它们的功能和机制作用,并评估它们在生物标志物开发和性别定制治疗策略中的效用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Alzheimer's Research & Therapy
Alzheimer's Research & Therapy 医学-神经病学
CiteScore
13.10
自引率
3.30%
发文量
172
审稿时长
>12 weeks
期刊介绍: Alzheimer's Research & Therapy is an international peer-reviewed journal that focuses on translational research into Alzheimer's disease and other neurodegenerative diseases. It publishes open-access basic research, clinical trials, drug discovery and development studies, and epidemiologic studies. The journal also includes reviews, viewpoints, commentaries, debates, and reports. All articles published in Alzheimer's Research & Therapy are included in several reputable databases such as CAS, Current contents, DOAJ, Embase, Journal Citation Reports/Science Edition, MEDLINE, PubMed, PubMed Central, Science Citation Index Expanded (Web of Science) and Scopus.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书